OncoMatch/Clinical Trials/NCT03808337
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Is NCT03808337 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Systemic Therapy/Standard of Care for triple negative breast cancer.
Treatment: Systemic Therapy/Standard of Care — This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Allowed: ALK targetable molecular alteration
Allowed: EGFR targetable molecular alteration
Allowed: ROS1 targetable molecular alteration
Disease stage
Required: Stage IV, DE NOVO STAGE IV
Metastatic disease required
Metastatic disease detected on imaging and histologically confirmed
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Natera, Inc. (Data and Specimen Analysis Only) · San Carlos, California
- Hartford Healthcare · Hartford, Connecticut
- WCHN Norwalk Hospital - Data Collection · Norwalk, Connecticut
- Baptist Alliance - McI · Miami, Florida
- Memorial Sloan Kettering Basking Ridge · Basking Ridge, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03808337 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV or DE NOVO STAGE IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify